Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Arch. cardiol. Méx ; 93(4): 435-441, Oct.-Dec. 2023. tab, graf
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1527721

ABSTRACT

Resumen Objetivo: Describir la evolución de las cadenas livianas libres séricas (CLL) en el período comprendido entre el trasplante cardíaco ortotópico (TCO) y el trasplante de células progenitoras hematopoyéticas (TCPH), la respuesta hematológica al año tras el TCPH y el tratamiento quimioterápico e inmunosupresor en pacientes con amiloidosis AL. Método: Serie de casos de pacientes consecutivos con diagnóstico de amiloidosis AL que recibieron TCO seguido de TCPH del Registro Institucional de Amiloidosis del Hospital Italiano de Buenos Aires, entre enero de 2010 y noviembre de 2021. Se reportaron los valores de CLL entre trasplantes y al año del TCPH. Las variables cuantitativas se describieron como mediana e intervalo intercuartil, y las variables categóricas como frecuencias absolutas y relativas. Resultados: De 106 pacientes con amiloidosis AL, seis tuvieron TCO seguido de TCPH. La mediana de edad fue de 55 años. La mayoría eran hombres (n = 5). En el período entre trasplantes, la CLL involucrada disminuyó en dos pacientes y se mantuvo estable en tres. Todos lograron la remisión hematológica completa al año del TCPH. Un solo paciente presentó recaída en el órgano sólido trasplantado. Tacrolimus, micofenolato de mofetilo y corticoides fue el esquema inmunosupresor utilizado después del TCO. Conclusiones: El TCO representa una opción de tratamiento en pacientes con falla cardíaca grave por amiloidosis, permitiendo luego un tratamiento intensivo con quimioterapia de inducción y TCPH. Si bien faltan estudios, la terapia inmunosupresora después del TCO podría tener algún efecto sobre las células plasmáticas clonales.


Abstract Objective: To describe the evolution of serum free light chains (FLC) in the period between orthotopic heart transplantation (OHT) and autologous stem cell transplantation (ASCT), the hematological response one year after ASCT and chemotherapy and immunosuppressive treatment in patients with AL amyloidosis. Method: Case series of consecutive patients diagnosed with AL amyloidosis who received OHT followed by ASCT from the Institutional Registry of Amyloidosis of the Italian Hospital of Buenos Aires, between January 2010 and November 2021. FLC values between transplants and at year post ASCT. Quantitative variables were described with their median and interquartile range. Categorical variables as absolute and relative frequencies. Results: Of 106 patients with AL amyloidosis, 6 had an OHT followed by ASCT. The median age was 55 years. Most were men (n = 5). In the period between transplants, the involved CLL decreased in two patients and remained stable in three. All achieved complete hematologic remission 1 year after ASCT. A single patient presented relapse in the transplanted solid organ. Tacrolimus, mycophenolate mofetil, and corticosteroids were the immunosuppressive regimen used after OHT. Conclusions: OHT represents a treatment option in patients with severe heart failure due to amyloidosis, allowing later intensive treatment with induction chemotherapy and ASCT. Although studies are lacking, immunosuppressive therapy after OHT might have some effect on clonal plasma cells.

2.
Rev. urug. cardiol ; 37(1): e304, jun. 2022. ilus, tab
Article in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1410055

ABSTRACT

Las amiloidosis son un grupo heterogéneo de patologías caracterizado por el depósito extracelular de proteínas fibrilares anormalmente plegadas que se depositan en los tejidos y ocasionan su disfunción. La calidad y expectativa de vida depende del órgano afectado y del grado de compromiso, la afectación cardíaca es la principal determinante de la sobrevida y calidad de vida. El diagnóstico requiere la biopsia tisular y tipificación de la proteína. Su detección tardía se asocia a inferior pronóstico y sobrevida. La forma más común de amiloidosis es la causada por depósito de cadenas livianas monoclonales (AL), para la cual nuevos agentes de inmuno y quimioterapia dirigidas a suprimir la clona de células plasmáticas han demostrado mejorar la sobrevida. Para la amiloidosis por transtiretina (ATTR), segunda en frecuencia, existen terapias estabilizadoras de la proteína y terapias dirigidas a detener su síntesis a través del silenciamiento genético. Esta revisión se dirige a describir las bases hematológicas útiles para el cardiólogo clínico.


The amyloidoses are a heterogeneous group of diseases caused by the extracellular deposition of abnormally folded fibrillar proteins in organs and tissues, causing their dysfunction. The quality and life expectancy depend on the affected organ, with cardiac involvement being the main determinant of survival and quality of life. Diagnosis requires tissue biopsy and protein typing. Its late detection is associated with a lower prognosis and survival. The most common form of amyloidosis is caused by monoclonal light chain (AL) deposition, for which new immunological agents and chemotherapy aimed at suppressing plasma cell cloning have been shown to improve survival. For transthyretin amyloidosis (ATTR), the second in frequency, there are protein-stabilizing therapies and therapies aimed at stopping its synthesis through genetic silencing. This review focuses on the hematological bases for the clinical cardiologist.


As amiloidoses são um grupo heterogêneo de patologias caracterizadas pela deposição extracelular de proteínas fibrilares anormalmente dobradas, que se depositam nos tecidos, causando sua disfunção. A qualidade e expectativa de vida dependem do órgão afetado e do grau de comprometimento, sendo o acometimento cardíaco o principal determinante da sobrevida e qualidade de vida. O diagnóstico requer biópsia tecidual e tipagem de proteínas. Sua detecção tardia está associada a um menor prognóstico e sobrevida. A forma mais comum de amiloidose é causada pela deposição monoclonal de cadeia leve (AL), para a qual novos agentes imuno e quimioterápicos destinados a suprimir a clonagem de plasmócitos demonstraram melhorar a sobrevida. Para a amiloidose por transtirretina (ATTR), segunda em frequência, existem terapias estabilizadoras de proteínas e terapias destinadas a interromper sua síntese por meio do silenciamento genético. Esta revisão enfoca a amiloidose sistêmica, com foco em bases hematológicas úteis para o cardiologista clínico.


Subject(s)
Humans , Amyloidosis/diagnosis , Biopsy , Diagnosis, Differential
3.
Rev. colomb. cardiol ; 28(6): 530-538, nov.-dic. 2021. tab, graf
Article in Spanish | LILACS, COLNAL | ID: biblio-1357227

ABSTRACT

Resumen Introducción La fibrosis endomiocárdica es una enfermedad cardiovascular olvidada, principal causa de cardiomiopatía restrictiva. Se estima que en el mundo hay 10-12 millones de personas con la enfermedad. La mayoría se restringen a zonas de África, Asia y, en Latinoamérica, en Brasil y Colombia. La etiología y la fisiopatología son poco comprendidas. Para su diagnóstico se deben tener en cuenta los datos del paciente, el cuadro clínico y los hallazgos ecocardiográficos. Presentamos los casos confirmados en un centro de referencia cardiovascular. Descripción de los casos: Se han documentado tres casos, de los cuales dos son mujeres. Todos debutaron con un cuadro insidioso de disnea con esfuerzo. Los hallazgos ecocardiográficos fueron disfunción diastólica con patrón restrictivo, insuficiencia moderada de válvulas auriculoventriculares e hipertensión pulmonar; en dos casos se encontraron imágenes anormales endocárdicas en el ventrículo izquierdo y se realizó biopsia endomiocárdica para confirmar el diagnóstico. Ninguno mejoró la clase funcional ni la frecuencia de hospitalizaciones. Conclusiones La fibrosis endomiocárdica debe considerarse en todo paciente con falla cardiaca con un patrón restrictivo asociado y con poca respuesta al manejo farmacológico convencional. Los pacientes presentados tenían hallazgos típicos de la enfermedad, con la particularidad de ser de edades mayores.


Abstract Introduction Endomyocardial fibrosis is one of the neglected cardiovascular disease, the main cause of restrictive cardiomyopathy. There are an estimated 10-12 million people with the disease worldwide. Most are restricted to areas of Africa, Asia and in Latin America in Brazil and Colombia. The etiology and pathophysiology are poorly understood. For its diagnosis, the patient's data, the clinical picture and the echocardiographic findings must be taken into account. We present the confirmed cases in a cardiovascular referral center. Description of the cases Three cases have been documented of which two are women. All debuted with insidious dyspnea on exertion. The echocardiographic findings were diastolic dysfunction with a restrictive pattern, moderate atrioventricular valve insufficiency, and pulmonary hypertension. In two cases, endocardial abnormal images were found in the left ventricle and an endomyocardial biopsy was performed to confirm the diagnosis. None improved functional class or frequency of hospitalizations. Conclusions Endomyocardial fibrosis should be considered in a patient with heart failure with an associated restrictive pattern, and with little response to conventional pharmacological management. The patients presented had typical findings of the disease with the particularity of being older.


Subject(s)
Humans , Endomyocardial Fibrosis , Cardiomyopathy, Restrictive , Eosinophilia , Heart Failure
4.
Arch. cardiol. Méx ; 91(2): 196-201, abr.-jun. 2021. tab, graf
Article in Spanish | LILACS | ID: biblio-1248785

ABSTRACT

Resumen Objetivo: La fibrosis endomiocárdica (FE) es una cardiomiopatía restrictiva infrecuente. En América Latina son escasos los reportes. En el presente trabajo se realiza una descripción de una serie de pacientes diagnosticados de FE en Colombia. Método: Realizamos una búsqueda en los registros de imágenes de resonancia magnética (RM) cardiaca realizadas en nuestra institución entre 2016 y 2019 en busca de pacientes con diagnóstico de FE. Se describieron sus características sociodemográficas, clínicas y de imagen. Resultados: Nueve pacientes fueron diagnosticados de FE (el 66.7% mujeres), con una edad promedio de 69 años. Los pacientes presentaron un promedio de 2.6 años de evolución. El principal síntoma referido fue disnea, seguido de síncope, dolor torácico y palpitaciones. En ninguno de ellos se sospechó FE como diagnóstico inicial. En cuanto a los hallazgos ecocardiográficos, se identificó compromiso predominante del ventrículo izquierdo, seguido de compromiso biventricular. Todos los pacientes presentaron patrón de llenado restrictivo con dilatación auricular izquierda severa. En el análisis retrospectivo se cumplieron los criterios de Mocumbi para el diagnóstico de FE en el 100% de los pacientes con gravedad moderada (77.8%). Las imágenes de RM mostraron función sistólica biventricular y volúmenes preservados. Se observó depósito focal de gadolinio subendocárdico a nivel apical y se confirmó la presencia de trombo en el 66% de los casos Conclusión:: La FE es una cardiomiopatía restrictiva infrecuente circunscrita a países tropicales. La mayoría de los pacientes en nuestra serie presentaron compromiso aislado del ventrículo izquierdo, seguido de compromiso biventricular, con función ventricular usualmente preservada.


Abstract Objective: Endomyocardial fibrosis (EF) is an unusual restrictive cardiomyopathy. In Latin America there are few reports. Here, we made a description of patients diagnosed with EF in Colombia. Method: We conducted a search in the records of cardiac magnetic resonance imaging (MRI) performed in our institution between 2016-2019 looking for patients with a diagnosis of EF; sociodemographic, clinical and imaging characteristics were described. Results: Nine patients were diagnosed with EF (66.7% female), with an average age of 69 years. Patients presented an average evolution of 2.6 years. The main reported symptom was dyspnea, followed by syncope, chest pain, and palpitations. None of them was initially suspected for EF. Regarding echocardiographic findings, predominant left ventricular involvement was identified, followed by bi-ventricular involvement. All the patients presented a restrictive filling pattern with severe left atrial dilation. In a retrospective analysis, Mocumbi criteria for diagnosis of EF were met in 100% of the patients, majority with moderate severity (77.8%). Cardiac MRI showed biventricular systolic function and volumes preserved. Focal subendocardial late gadolinium enhancement was observed on the apex and apical thrombus was confirmed in 66% of the patients Conclusion: FE is an uncommon restrictive cardiomyopathy limited to tropical countries. Most of patients in our series presented isolated involvement of left ventricle, followed by bi-ventricular involvement, with ventricular function usually preserved.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Cardiomyopathy, Restrictive/etiology , Cardiomyopathy, Restrictive/diagnostic imaging , Endomyocardial Fibrosis/diagnostic imaging , Heart Failure , Magnetic Resonance Imaging , Retrospective Studies , Colombia , Contrast Media , Gadolinium
5.
Iatreia ; 34(1): 64-70, ene.-mar. 2021. graf
Article in Spanish | LILACS | ID: biblio-1154359

ABSTRACT

RESUMEN La amiloidosis AL (antes denominada amiloidosis primaria) es una entidad sistémica poco frecuente, con incidencia desconocida en el mundo, que puede llegar a presentar compromiso cardíaco en casi la mitad de los pacientes, llevando a una cardiomiopatía restrictiva por depósito de tejido amiloide. A continuación, presentamos 3 casos de pacientes que consultaron por falla cardíaca aguda y síncope, en quienes finalmente se confirmó el diagnóstico de amiloidosis AL. Al final, se realiza una breve revisión de la literatura, enfatizando en los elementos clínicos para un diagnóstico temprano.


SUMMARY AL amyloidosis (formerly called primary amyloidosis) is a rare systemic entity, with an unknown incidence in the world, which can develop heart involvement in almost half of patients, leading to restrictive cardiomyopathy by amyloid tissue deposit. We present 3 cases of patients who consulted for acute heart failure and syncope, in which the diagnosis of AL amyloidosis was finally confirmed. We conclude with a brief review of the literature, emphasizing clinical elements for an early diagnosis.


Subject(s)
Humans , Aged , Syncope , Heart Failure , Amyloid , Cardiomyopathy, Restrictive , Heart
6.
Rev. costarric. cardiol ; 22(2)dic. 2020.
Article in Spanish | LILACS, SaludCR | ID: biblio-1389005

ABSTRACT

Resumen La pericarditis constrictiva y la miocardiopatía restrictiva son enfermedades raras caracterizadas por síntomas de insuficiencia cardíaca congestiva. El objetivo de este estudio es mostrar el diagnóstico diferencial de estas dos patologías, mediante strain auricular y establecer su correlación con la histopatología de corazones correspondientes. Se analizan 2 casos clínicos representativos de cada una de estas patologías. Se analizan sus presentaciones clínicas, los datos ecocardiograficos y en ambos casos se realizaron biopsias endomiocardicas con lo cual se presenta la correlación histológica. El strain auricular permitió evaluar la afección de las aurículas, consideramos que el strain auricular disminuido podría estar relacionado con la presencia de fibrosis.


Abstract Histopathology and Atrial Strain in Constrictive Pericarditis and restrictive cardiomyopathy Constrictive pericarditis and restrictive cardiomyopathy are rare diseases characterized by congestive heart failure symptoms. The aim of this study is to show the differential diagnosis of these two pathologies using strain and to establish their correlation with histopathology of the corresponding hearts. Two representative clinical cases of each of these pathologies are analyzed. Their clinical presentations, echocardiographic data, and endomyocardial biopsies were performed in both cases, thus presenting the histological correlation. Atrial strain allowed us to evaluate the affection of the atria, we consider that decreased atrial strain could be related to the presence of fibrosis.


Subject(s)
Humans , Male , Middle Aged , Pericarditis, Constrictive/diagnosis , Cardiomyopathy, Restrictive/diagnosis , Costa Rica
7.
Arq. bras. cardiol ; 115(5): 945-948, nov. 2020. tab, graf
Article in Portuguese | SES-SP, LILACS | ID: biblio-1142261

ABSTRACT

Resumo Evidências recentes sugerem que a amiloidose cardíaca é uma doença amplamente subdiagnosticada, particularmente na sua forma ligada à transtirretina, podendo ser uma causa comum de insuficiência cardíaca com fração de ejeção preservada (ICFEP) no idoso. Os novos paradigmas sobre a doença incluem o desenvolvimento de novas terapias específicas que modificam a história natural da doença. Este artigo traz uma síntese destes novos conceitos.


Abstract Recent evidence suggests cardiac amyloidosis (CA) is a mostly underdiagnosed condition, particularly in the transthyretin-mediated form, and is a frequent cause of heart failure with preserved ejection fraction (HFpEF) in the elderly. New paradigms about CA also involve the development of disease-modifying specific therapies. This article summarizes these new concepts.


Subject(s)
Humans , Aged , Heart Failure/etiology , Amyloidosis , Stroke Volume , Prealbumin
8.
Pesqui. vet. bras ; 40(5): 389-398, May 2020. tab, ilus
Article in English | LILACS, VETINDEX | ID: biblio-1135627

ABSTRACT

Cardiomyopathies are considered one of the most important causes of heart failure in cats and are subdivided into three main morphological types: hypertrophic (HCM), dilated (DCM), and restrictive (RCM). This study aimed to determine the frequency and types of cardiomyopathies in cats diagnosed in southern Brazil, with an emphasis on their epidemiological and pathological aspects. Necropsy reports filed in a veterinary pathology laboratory were reviewed, and cats diagnosed with cardiomyopathy were selected for the study. Animal identification data, history and clinical signs, and gross lesions, were reviewed and compiled. During the study period, 1.594 cat necropsies were performed, of which 72 (4.5%) comprised a diagnosis of cardiomyopathy. HCM was the most frequent followed by CMR and CMD, representing 77.8%, 12.5% and 9.7%, respectively. Age ranged from three months to 18 years, with a median age of seven years. In relation to sex, 62.5% were males and 37.5% females. In 76.4% of the cases, it affected cats without a breed defined. Restrictive mixed dyspnea and hydrothorax were the main signs or findings of the clinical examination. Sudden death and acute paresis of the pelvic limbs due to aortic thromboembolism have also been described. In HCM, myocardial thickening was observed, with a reduction in the ventricular chamber. Hypertrophy, disarray, and fibrosis of the myofibers were the main histological findings. In RCM, whitish and thickened endocardium was seen in most cases. DCM was characterized by dilated cardiac chambers, and microscopic examination revealed no significant findings. The main extra cardiac lesions revealed pulmonary edema and congestion, hydrothorax and chronic passive congestion of the liver. Cardiomyopathies are important causes of death in cats and should be included in the differential diagnosis of patients with cardio respiratory clinical signs and in cases related to sudden death and acute paresis of the pelvic limbs.(AU)


As cardiomiopatias são consideradas umas das mais importantes causas de insuficiência cardíaca em gatos e são subdivididas morfologicamente em três principais tipos: cardiomiopatia hipertrófica (CMH), dilatada (CMD) e restritiva (CMR). Este trabalho teve como objetivo determinar a frequência e os tipos de cardiomiopatias em gatos diagnosticados no Sul do Brasil, abordando seus aspectos epidemiológicos e patológicos. Foram revisados os laudos de necropsias de gatos e selecionados para o estudo de diagnóstico de cardiomiopatia. Os dados referentes à identificação do animal, o histórico/sinais clínicos e lesões macroscópicas foram revisados e compilados. No período estudado, foram realizadas 1.594 necropsias de gatos, destas, 72 (4,5%) compreenderam diagnóstico de cardiomiopatia. A CMH foi a mais frequente seguida pela CMR e CMD, representando 77,8%, 12,5% e 9,7%, respectivamente. A idade variou de três meses a 18 anos, com a idade mediana de sete anos. Em relação ao sexo, 62,5% eram machos e 37,5% fêmeas. Em 76,4% dos casos, afetou gatos sem raça definida. Dispneia mista restritiva e hidrotórax foram os principais sinais ou achados do exame clínico. Morte súbita e paresia aguda de membros pélvicos em razão do tromboembolismo aórtico também foram descritos. Na CMH, observou-se espessamento do miocárdio, com redução da câmara ventricular. Hipertrofia, desarranjo e fibrose das miofibras foram os principais achados histológicos. Na CMR, visualizou-se endocárdio esbranquiçado e espessado na maioria dos casos. A CMD caracterizou-se pela dilatação das câmaras cardíacas, e sem lesão histológica significante. As principais lesões extracardíacas encontradas foram edema e congestão pulmonares, hidrotórax e congestão passiva crônica do fígado. As cardiomiopatias são causas importantes de morte em gatos, devem ser incluídas no diagnóstico diferencial de pacientes com sinais clínicos cardiorrespiratórios e também em casos relacionados a morte súbita e paresia aguda dos membros pélvicos.(AU)


Subject(s)
Animals , Cats , Cardiomyopathy, Hypertrophic/pathology , Cardiomyopathy, Hypertrophic/veterinary , Cardiomyopathy, Hypertrophic/epidemiology , Cardiomyopathy, Restrictive/pathology , Cardiomyopathy, Restrictive/veterinary , Cardiomyopathy, Restrictive/epidemiology , Cardiomyopathy, Dilated/pathology , Cardiomyopathy, Dilated/veterinary , Cardiomyopathy, Dilated/epidemiology , Cat Diseases
9.
Article | IMSEAR | ID: sea-212028

ABSTRACT

Background: Endomyocardial fibrosis has varied presentatation and difficult to diagnose. Aim to elucidate the role of Cardiac Magnetic Resonance (CMR) imaging in the evaluation of Endomyocardial Fibrosis (EMF) and to devise diagnostic criteria for the disease.Methods: Retrospective analysis of cases of restrictive cardiomyopathy referred for Magnetic resonance imaging over a period of 5 years. All patients underwent 1.5 T CMR imaging (Magnetom Avanto, Siemens, Germany) with standard cardiomyopathy protocol. Criteria for diagnosis of RCM included normal sized ventricles, normal/reduced systolic function, uni-/bi-atrial enlargement, normal pericardium and absent septal bounce. Cases diagnosed as EMF on CMR were included in this study. Statistical analysis performed using SPSS software.Results: EMF was diagnosed in 20 patients (31%) [12 males; age 39±18 years]. Ten patients had Right Centricular (RV) EMF, 3 had Left Ventricular (LV) EMF, while 7 had bi-ventricular EMF. Oedema indicating ongoing inflammation was seen in 4 (20%) cases. Apical thrombus was seen in 8(40%) cases and was present in 35% cases of RV and 20% cases of LV involvement. Subendocardial delayed enhancement was always present in the involved ventricle. The RV apex was obliterated in 100% of patients with RV EMF, while LV apex was similarly obliterated in 66% cases with LV disease. Mild-moderate pericardial effusion was observed in 8 patients. On the basis of CMR findings, the disease was classified as early necrotic phase in 1, thrombotic necrotic in 4 and late fibrotic phase in 13 and of different stages in ventricles in 2 cases.Conclusions: EMF was the commonest cause of RCM in this series. Major diagnostic criteria of EMF on CMR include subendocardial delayed enhancement and apical obliteration. Oedema and thrombus are variable findings, depending on disease severity.

10.
Medicina (B.Aires) ; 79(4): 284-286, ago. 2019. ilus, graf
Article in Spanish | LILACS | ID: biblio-1040523

ABSTRACT

La endomiocardiofibrosis es una causa de miocardiopatía restrictiva frecuente en la región de África subsahariana, aunque poco frecuente en nuestra población. Posee estrecha relación con la presencia de hipereosinofilia en sangre y tiene alta morbimortalidad. La hepatitis hipóxica es una afección clínica con un patrón enzimático característico, muy prevalente en unidades de cuidados intensivos y elevada mortalidad. Se reconocen múltiples mecanismos fisiopatológicos, como la isquemia, la congestión venosa y la alteración en la utilización de oxígeno del hepatocito. Describimos el caso de u na paciente de 35 años, consumidora de cocaína, con diagnóstico de endomiocardiofibrosis secundario a síndrome hipereosinofílico idiopático que presentó shock cardiogénico y hepatitis hipóxica asociada. Evolucionó favorablemente con el tratamiento de sostén adecuado.


Endomyocardial fibrosis is a restrictive cardiomyopathy with high morbidity and mortality rates, prevalent in the sub-Saharan Africa region but infrequent in our population. It has a close relation with blood hypereosinophilia. Hypoxic hepatitis is frequently observed in intensive care units and its diagnosis is clinical. It shows a typical enzyme pattern with high mortality too. There are multiple mechanisms responsible for this condition, such as ischemia, passive congestion and dysoxia. We described the case of a 35 year-old cocaine addict woman diagnosed with endomyocardial fibrosis and hypereosinophilic syndrome who developed cardiogenic shock with hypoxic hepatitis. The patient evolved favorably with the appropriate treatment.


Subject(s)
Humans , Female , Adult , Shock, Cardiogenic/complications , Hypereosinophilic Syndrome/complications , Cocaine-Related Disorders/complications , Endomyocardial Fibrosis/etiology , Hepatitis/complications , Endomyocardial Fibrosis/diagnosis , Hypoxia/complications
11.
Rev. costarric. salud pública ; 28(1): 74-82, ene.-jun. 2019. graf
Article in Spanish | LILACS | ID: biblio-1013977

ABSTRACT

Resumen La amiloidosis es una enfermedad multisistémica, originada por un plegamiento proteico anormal el cual a su vez genera su depósito y acumulación en diferentes tejidos. A nivel cardiovascular, el amiloide se deposita en el tejido miocárdico generando las manifestaciones típicas de la enfermedad. Presenta hallazgos electrocardiográficos y ecocardiográficos distintivos que proporcionan una ayuda invaluable en el diagnóstico de la amiloidosis cardiaca. En el presente artículo se expone un caso de un paciente portador de amiloidosis AL, quien exhibe síntomas de falla cardiaca y en el cual se documenta posteriormente severo compromiso cardiovascular. Además, se presenta una revisión de las manifestaciones cardiovasculares y el diagnóstico de dicha patología.


Abstract Amyloidosis is a multisystemic disease, originated by an abnormal protein folding which in turn generates its deposit and accumulation in different tissues. At a cardiovascular level, amyloid is deposited in the myocardial tissue and thus generating the typical manifestations of the disease. It presents distinctive electrocardiographic and echocardiographic findings that provide invaluable help in the diagnosis of cardiac amyloidosis. In this article, a case of a patient with AL amyloidosis is presented. Said patient developed symptoms of heart failure, which later progressed into severe cardiovascular compromise. Furthermore, a review of the cardiovascular manifestations and the diagnosis of said pathology is presented.


Subject(s)
Humans , Female , Middle Aged , Heart Diseases , Amyloidosis/complications , Amyloidosis/diagnostic imaging , Costa Rica
12.
Article | IMSEAR | ID: sea-194338

ABSTRACT

Amyloidosis refers to a group of disorders characterized by extracellular deposition of protein fibrils. Primary systemic amyloidosis is commonly due to an underlying plasma cell dyscrasia. Infiltrative amyloid cardiomyopathy is a rare cause of predominantly diastolic myocardial disease. Restrictive cardiomyopathy is the main finding in cardiac amyloidosis and results from the replacement of normal myocardial contractile elements by infiltration and interstitial deposits of amyloid, leading to alterations in cellular metabolism, calcium transport, receptor regulation, and cellular edema. Injury can also occur from circulating light chains in the absence of amyloid fibril formation. Cardiac amyloidosis should be considered in any patient presenting with congestive heart failure, preserved systolic function, and a discrepancy between a low QRS voltage on electrocardiography and an apparent left ventricular hypertrophy on sonogram. The pattern of left ventricular diastolic dysfunction changes during the course of amyloidosis and the classically described restrictive physiology occurs only in advanced stages of the disease. This is a case report where an unusual extensive cutaneous and cardiac involvement provided the sign of widespread systemic deposition of amyloid protein which eventually led to the diagnosis of multiple myeloma.

13.
Medicina (B.Aires) ; 78(6): 395-398, Dec. 2018. ilus, graf, tab
Article in Spanish | LILACS | ID: biblio-976136

ABSTRACT

La amiloidosis cardíaca del subtipo transtirretina (ATTR) es una cardiopatía restrictiva que causa insuficiencia cardíaca en un número considerable de pacientes. Su identificación temprana permitiría brindar tratamientos específicos. Sin embargo, el diagnóstico de ATTR es complejo y requiere métodos invasivos. Los fosfonatos marcados con 99mTecnecio han demostrado ser útiles para el diagnóstico, aunque en Argentina la experiencia es escasa. Nuestro objetivo fue evaluar la utilidad de este método para diagnosticar de forma no invasiva la ATTR. Se estudiaron 46 pacientes entre septiembre de 2016 y enero de 2018 por sospecha de amiloidosis cardíaca. Se evaluó el grado de captación cardíaca con relación al tejido óseo, a la hora, mediante dos métodos: semi-cuantitativo y cuantitativo. El diagnóstico definitivo de amiloidosis y el subtipo específico fue asignado por el centro de miocardiopatías de nuestra institución siguiendo recomendaciones internacionales. Una captación ≥ grado II presentó un valor predictivo positivo del 96% y negativo del 100% para el diagnóstico de amiloidosis cardíaca ATTR. El valor de corte de 1.38 en la relación corazón/pulmón presentó una sensibilidad del 96% y una especificidad del 100% para discriminar entre pacientes con ATTR de aquellos con amiloidosis por cadenas livianas u otras afecciones (área bajo la curva relación corazón/pulmón = 0.95 p < 0.001). La centellografía con fosfonatos marcados demostró ser un método no invasivo útil para diagnosticar ATTR. Dado que además de ser no invasiva, es una herramienta de bajo costo y ampliamente disponible en nuestro medio, su aplicación puede redundar en un beneficio clínico para muchos pacientes.


Transthyretin cardiac amyloidosis (ATTR) is a restrictive cardiomyopathy that leads to heart failure in considerable number of patients. Early diagnosis allows specific treatment options. However, ATTR diagnosis is complex and requires invasive procedures. The utility of 99mTc-phosphate tracers for non-invasive diagnosis is well-known but the experience in Argentina is insufficient. The aim of this work was to assess the utility of 99mTc-phosphate tracers for the diagnosis of ATTR. A total of 46 scintigraphies for detection of cardiac amyloidosis performed between September 2016 and January 2018 were analyzed. Cardiac retention after one hour was assessed in relation to bone uptake using two methods: A semi-quantitative visual score (grade 0 = absent, I = low II = moderate-III = high) and a quantitative method (heart/lung ratio). The final diagnosis and the amyloidosis subtype were carried out by our institution cardiomyopathy team according to international guidelines. The positive and negative predictive values for Grade ≥ II were 96% and 100% respectively for diagnosis of ATTR. Using 1.38 as cut-off value for heart/lung ratio the sensitivity and the specificity were 96% and 100%, respectively for differentiating transthyretin cardiac amyloidosis from light-chain cardiac amyloidosis and other cardiopathies. Scintigraphy with 99mTc-phosphate tracers enable noninvasive diagnosis and subtype classification of cardiac amyloidosis. The use of this non-invasive, inexpensive and widely available tool will result in better patient management.


Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Phosphates , Radionuclide Imaging/methods , Technetium Compounds , Amyloidosis/diagnostic imaging , Cardiomyopathies/diagnostic imaging , Predictive Value of Tests , Reproducibility of Results , Statistics, Nonparametric , Radiopharmaceuticals , Amyloidosis/physiopathology , Cardiomyopathies/physiopathology
14.
Horiz. méd. (Impresa) ; 18(4): 81-89, oct.-dic. 2018. ilus
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1012259

ABSTRACT

La amiloidosis cardiaca es una entidad clínica poco frecuente y por tanto poco conocida. Su presentación, por ser una enfermedad infiltrativa debido al depósito extracelular del amiloide en la pared cardiaca, es la de una cardiomiopatía del tipo restrictivo, que si bien puede ser sistémica, es la afección cardiaca la que determina su mal pronóstico. Se presenta el caso de un paciente de 38 años de edad, que fue hospitalizado por disnea y fatiga severa, y al que se diagnosticó mieloma múltiple IgA de cadenas ligeras lambda, estadio clínico IIIB, e inició tratamiento con ciclofosfamida, talidomida y dexametasona. El paciente abandonó el tratamiento y regresó luego de un año y 2 meses con la enfermedad avanzada y con presencia de amiloidosis. El paciente evoluciona tórpidamente y fallece.Se realiza una revisión de la literatura médica sobre los tipos de amiloidosis, la fisiopatología, los métodos diagnósticos y el tratamiento.


Cardiac amyloidosis is a rare clinical entity and, therefore, almost unknown. It shows as a restrictive cardiomyopathy, since it is an infiltrative disease caused by the extracellular deposition of amyloids in the cardiac wall. Although it may be systemic, the heart condition determines its poor prognosis. This is the case of a 38-year-old patient who was admitted for dyspnea and severe fatigue. He was diagnosed with IgA multiple myeloma, lambda light chains, clinical stage IIIB, and initiated treatment with cyclophosphamide, thalidomide and dexamethasone. The patient stopped the treatment, and returned after one year and 2 months with an advanced disease and presence of amyloidosis. The patient progressed torpidly and eventually died. A review of the medical literature is performed concerning amyloidosis types, physiopathology, diagnostic methods and treatment.

15.
Rev. colomb. cardiol ; 24(4): 407-407, jul.-ago. 2017. tab, graf
Article in Spanish | LILACS, COLNAL | ID: biblio-900552

ABSTRACT

Resumen Las miocardiopatías son trastornos intrínsecos del músculo cardíaco. Presentan fenotipos diferenciales que determinan su clasificación; estos son: dilatada, hipertrófica, restrictiva, displasia arritmogénica del ventrículo derecho y no clasificadas. Las miocardiopatías restrictivas se caracterizan por ventrículos de tamaño normal, con grosores de pared normales o ligeramente aumentados, paredes rígidas, disfunción diastólica severa y llenado restrictivo con presiones elevadas. Una de las formas más comunes de miocardiopatía restrictiva es la fibrosis endomiocárdica la cual es endémica en algunas zonas tropicales especialmente en África (países de bajos ingresos), pero en nuestro medio hay pocos reportes de aparición. Su etiología es desconocida, aunque existen diversos mecanismos que han sido involucrados en su fisiopatología. Su diagnóstico se basa en estudios imagenológicos (ecocardiograma transtorácico y resonancia magnética nuclear cardíaca). El pronóstico es muy pobre, y usualmente se diagnostica en etapas muy avanzadas de la enfermedad. Se describe el caso de una paciente femenina, adulta media, que debutó con cardiopatía restrictiva, cuyo diagnóstico final fue fibrosis endomiocárdica.


Abstract Cardiomyopathies are intrinsic conditions of the cardiac muscle. They present differential phenotypes that determine their classification. These are: dilated, hypertrophic, restrictive, arrhythmogenic right ventricular and unclassified. Restrictive cardiomyopathies are characterised by larger than normal ventricles with normal or slightly enlarged thickness of the walls, rigid walls, severe diastolic dysfunction and restrictive filling with high pressures. One of the most common restrictive cardiomyopathies is endomyocardial fibrosis, which is endemic to some tropical areas, especially Africa (low income countries), but there are few reports of its occurrence in our environment. Its aetiology is unknown, but there are several mechanisms that have been involved in its pathophysiology. Its diagnosis is based in imaging studies (transthoracic echocardiogram, cardiac nuclear magnetic resonance). Prognosis is very poor, and it is usually diagnoses in the latest stages of the disease. The case of a female, average adult patient that debuted with restrictive cardiomyopathy with a final diagnosis of endomyocardial fibrosis is described.


Subject(s)
Humans , Female , Middle Aged , Cardiomyopathy, Restrictive , Endomyocardial Fibrosis , Magnetic Resonance Spectroscopy , Cardiomyopathies
16.
Rev. colomb. cardiol ; 24(1): 59-59, ene.-feb. 2017. tab, graf
Article in Spanish | LILACS, COLNAL | ID: biblio-900493

ABSTRACT

Resumen La fibrosis endomiocárdica o endocarditis de Löffler es una patología de causa todavía desconocida, esta puede presentarse durante la evolución de diversas enfermedades de causa infecciosa, tumoral, autoinmune, medicamentos, etc. En muchos casos el presentar eosinofilia moderada (más de 1500 eosinófilos/microlitro) por largos períodos de tiempo puede producir toxicidad en diferentes órganos, entre ellos el corazón, produciendo disfunción del mismo por infiltración directa lo cual daña el tejido y también por las proteínas encontradas en los gránulos, principalmente la proteína catiónica eosinofílica y la proteína básica mayor que tienen predilección por el tejido endocárdico, llevando a su destrucción celular, lo que se traducirá en engrosamiento y fibrosis del subendocardio. Estas alteraciones conllevan a la cardiomiopatía restrictiva, siendo la fibrosis endomiocárdica su principal causa. Se presenta el caso de un paciente masculino de 30 a˜nos de edad, que ingresa al hospital por un cuadro de falla cardiaca aguda con evidencia en el ecocardiograma de ingreso de un componente restrictivo biventricular, el cual en diferentes series se presenta hasta en el 51% de los casos. El paciente presentaba una enfermedad hematológica de base, donde la eosinofilia era persistente durante más de 6 meses.


Abstract Endomyocardial fibrosis or Löffler endocarditis is a condition whose cause still remains unknown. It can develop during the progress of multiple infectious or tumour diseases, medication, etc. In many cases, showing moderate eosinophilia (more than 1500 eosinophils/ microliter) for long periods of time can cause organ toxicity, among them the heart. This produces a dysfunction of the heart due to direct infiltration, which damages the tissue, and also due to the proteins found in the granules, mostly eosinophil cationic protein and major basic protein, which have a predilection for endocardial tissue, leading to their cell destruction, which will translate into a subcardial enlargement and fibrosis. These alterations result in restrictive cardiomyopathy, endomyocardial fibrosis being their main cause. We present the case of a 30 year-old male patient who is admitted at the hospital due to acute heart failure with an admission echocardiogram that evidenced a restrictive biventricular component, present in up to 51% of the cases in different series. The patient had a base hematological disorder, where eosinophilia had been persistent for more than 6 months.


Subject(s)
Humans , Male , Adult , Cardiomyopathy, Restrictive , Thrombosis , Endocardium , Inflammation
17.
Korean Circulation Journal ; : 413-417, 2017.
Article in English | WPRIM | ID: wpr-72829

ABSTRACT

The fact that different types of cardiomyopathies can be manifested by the same sarcomere protein gene mutation in a single family is well known. However, mixed features of different types of cardiomyopathies in a single patient have not been well appreciated. We identified a novel mutation in cardiac troponin I3 (Arg186Gly) in the present case, and two of the family members showed mixed morphologic features of hypertrophic cardiomyopathy and left ventricular non-compaction. Moreover, both the features of cardiomyopathies were not apparent for each type of cardiomyopathy. In the patient's family, four other members had unexpected deaths before the age of 30.


Subject(s)
Humans , Cardiomyopathies , Cardiomyopathy, Hypertrophic , Cardiomyopathy, Restrictive , Sarcomeres , Troponin
18.
Medical Journal of Chinese People's Liberation Army ; (12): 1039-1044, 2017.
Article in Chinese | WPRIM | ID: wpr-694054

ABSTRACT

Objective To explore whether suberoylanilide hydroxamic acid (SAHA,br.Vorinostat,a kind of histone deacetylase inhibitor) can improve the diastolic function of restrictive cardiomyopathy (RCM) mice by up-regulating the expression of wild type cardiac troponin I (WT-cTnI).Methods Sixteen male cTnI R193H mice were employed and divided into SAHA group (n=6),dimethyl sulfoxide (DMSO) group (n=5) and control groups (n=5).Mice were subcutaneously injected with 50mg/kg SAHA in SAHA group,with 1ml/kg DMSO in DMSO group and with 1ml/kg normal saline in control group,respectively.The total treatment duration lasted for 56 days.Western blotting was performed to determine the levels of acetylated histone H3 (acH3) and the expression of cTnI.The transcription levels of Tnni3 were detected with RT-qPCR.The levels of acH3 in Tnni3 promoter key area were detected with chromatin immunoprecipitation (ChIP).The data of diastolic function measurements were collected using high frequency echocardiography.Results Compared to control group,the acH3 levels in nucleus and in Tnni3 promoter key area increased significantly in SAHA group (P<0.05).The acH3 level showed no significant difference between SAHA group and DMSO group (P>0.0S),but the specific acH3 level in Tnni3 promoter key area increased significantly in SAHA group compared to that in DMSO group (P<0.05).The expression of cTnI protein and Tnni3 mRNA showed no significant difference among the 3 groups.Compared to the control group,Tei index and E/A ratio increased in DMSO group.Left ventricle fractional shortening (LVFS),left ventricle ejection fraction (LVEF),stroke volume (SV),cardiac output (CO),isovolumic relaxation time (IVRT),E peak deceleration time (DT),early diastolic blood flow (E velocity) and late diastolic filling flow (A velocity) showed no significant difference between DMSO group and control group.IVRT,DT and Tei index increased,and E velocity and A velocity decreased in SAHA group compared to that in control group.Furthermore,LVFS,LVEF,SV and CO were decreased in SAHA group compared to that in control group (P<0.05).Similarly,IVRT increased (P<0.05) and LVFS,LVEE CO,E velocity and E/A ratio decreased in SAHA group compared to that in DMSO group.Conclusions SAHA may up-regulate the acH3 level in GATA and MEF2 binding site of Tnni3 promoter of RCM mice.However,SAHA may have no effect on the expression and transcription of Tnni3 in heart.Further studies are needed to confirm whether SAHA has any toxic effect on cardiac function.

19.
Chinese Journal of Applied Clinical Pediatrics ; (24): 34-37, 2017.
Article in Chinese | WPRIM | ID: wpr-505107

ABSTRACT

Objective To evaluate the diagnostic value of invasive cardiac catheterization for restrictive cardiomyopathy (RCM) and constrictive pericarditis (CP).Methods Twenty-seven children with CP or RCM hospitalized in Department of Cardiology,Shanghai Children's Medical Center,School of Medicine,Shanghai Jiaotong University from February 2002 to December 2015,were selected,including 10 patients who had been surgically documented CP and 17 patients with RCM who underwent cardiac catheterization.Intracardiac pressure waveforms were recorded and all the measurement indexes of pressure of all the patients were analyzed.The changes of cardiac pressure under deep breathing in 9 patients with local anesthesia was recorded.Results There were significant differences in pulmonary artery pressure,difference between left ventricular end-diastolic pressure (LVEDP) and right ventricular end-diastolic pressure (RVEDP),and the ratio of RVEDP/right ventricular systolic pressure between group RCM and group CP [(50.2 ± 12.0) mmHg(1 mmHg =0.133 kPa) vs.(38.1 ±6.8) mmHg,(7.8±5.5) mmHgvs.(1.8 ±4.7) mmHg,0.27 ±0.10vs.0.45 ± 0.20,respectively;t =2.912,2.787,2.418,all P < 0.05].However,there was overlapping for these criteria,and the predictive sensitivity of any of the criteria was less than 66.7%.In patients with CP,reciprocal changes in the filling between right ventricle and left ventricle occurred during respiration.In patients with RCM,the right ventricle and left ventricle pressures moved concordantly with respiration.The systolic area index was greater in group CP than that in group RCM (1.20 ± 0.03 vs.0.70 ± 0.14),and the difference was significant (t =6.152,P < 0.01).The systolic area index had a sensitivity of 100.0% and a predictive accuracy of 100.0% for the identification of patients with surgically proven CP.Conclusions Measurements in catheterization,especially the ratio of right ventricular to left ventricular systolic area during inspiration and expiration is a reliable catheterization criterion for differentiating CP from RCM.

20.
Rev. chil. cardiol ; 36(2): 127-131, 2017. ilus, tab
Article in Spanish | LILACS | ID: biblio-899577

ABSTRACT

Endomyocardial fibrosis is a known and prevalent cause of restrictive cardiomyopathy in countries of Equatorial Africa, but very rare elsewhere. Although the diagnosis in endemic countries is established by the presence of certain echocardiographic criteria, the gold standard is the endomyocardial biopsy, which shows fibrous tissue in the endocardium. An acute and subacute phase can be distinguished, with associated mortality due to complications of heart failure. In contrast, the chronic phase presents less aggressive behavior, with progression of symptoms. In this phase, surgical treatment may improve survival. We present the case of a 44-year-old patient with good clinical control under pharmacological treatment after 14 months of follow-up.


Subject(s)
Humans , Female , Adult , Cardiomyopathy, Restrictive/etiology , Endomyocardial Fibrosis/complications , Biopsy/methods , Echocardiography , Chronic Disease , Endomyocardial Fibrosis/diagnosis , Endomyocardial Fibrosis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL